The estimated Net Worth of Venture Fund X, L.P.Atlas V... is at least $83.2 Milhão dollars as of 11 March 2024. Venture V owns over 353,357 units of Kymera Therapeutics stock worth over $37,106,719 and over the last 2 years Venture sold KYMR stock worth over $46,059,684.
Venture has made over 5 trades of the Kymera Therapeutics stock since 2022, according to the Form 4 filled with the SEC. Most recently Venture sold 353,357 units of KYMR stock worth $14,911,665 on 11 March 2024.
The largest trade Venture's ever made was selling 382,244 units of Kymera Therapeutics stock on 14 December 2022 worth over $11,987,172. On average, Venture trades about 274,159 units every 100 days since 2022. As of 11 March 2024 Venture still owns at least 828,830 units of Kymera Therapeutics stock.
You can see the complete history of Venture V stock trades at the bottom of the page.
Over the last 4 years, insiders at Kymera Therapeutics have traded over $179,227,903 worth of Kymera Therapeutics stock and bought 2,497,406 units worth $70,844,455 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Bros. Advisors Lp667, L.P.B..., eGroup, Llc Green Jeremy Red.... On average, Kymera Therapeutics executives and independent directors trade stock every 14 days with the average trade being worth of $3,989,455. The most recent stock trade was executed by Jeffrey W. Albers on 26 August 2024, trading 5,000 units of KYMR stock currently worth $51,700.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
Kymera Therapeutics executives and other stock owners filed with the SEC include: